TY - JOUR
T1 - COPD patients’ characteristics, usual care, and adherence to guidelines
T2 - The Greek UNLOCK study
AU - On behalf of the Greek UNLOCK team
AU - Tsiligianni, Ioanna
AU - Kampouraki, Maria
AU - Ierodiakonou, Despo
AU - Poulonirakis, Ioannis
AU - Papadokostakis, Polyvios
AU - Lintovoi, Eleftheria
AU - Karanassos, Dimitris
AU - Maltezis, Kyriakos
AU - Chorti, Maria
AU - Petrovitsos, Evangelos
AU - Dimopoulou, Sofia
AU - Hamind, Sam
AU - Gialamas, Ioannis
AU - Athanasiou, Polyxeni
AU - Bempi, Vasiliki
AU - Lambraki, Irene
N1 - Publisher Copyright:
© 2019 Tsiligianni et al.
PY - 2019
Y1 - 2019
N2 - Purpose: GOLD guidelines classify COPD patients into A-D groups based on health status as assessed by COPD Assessment Test (CAT) or mMRC tools and exacerbations and recommend single or dual long-acting bronchodilators as maintenance therapy, with additional inhaled corticosteroids (ICS) if the disease remains uncontrolled. We aimed to classify primary care COPD patients into A-D groups, assess usual treatment and adherence to guidelines, potential mismatches between CATand mMRC-based classification and described symptoms within groups. Patients and methods: A total of 257 primary care COPD patients were enrolled between 2015 and 2016 in Greece. Physicians used structured interviews to collect cross-sectional data including demographics, symptoms, CAT, mMRC scores, and medications. Patients were classified into A-D groups based on CAT and mMRC, and prevalence of symptoms and medication was estimated within A-D groups. Interviews with physicians were also performed to explore additional issues about treatment and adherence to guidelines. Results: Mean (SD) age was 65 (12.3) years with 79% males. The majority of patients reported uncontrolled symptoms (91% and 61% with ≥10 CAT or ≥2 mMRC scores, respectively). Thirty-seven percentage had ≥2 exacerbations in the past year. Group B was the largest followed by Groups D, A, and C. Patients were classified as more severe by CAT than by mMRC. In all groups, the majority were treated with combined long-acting beta agonist/ICS (>50%). When patients were asked to report their main symptoms, dyspnea and cough were the most important symptoms mentioned, and there was a great variation between the A-D groups. However, Groups A-C reported mainly morning symptoms, whereas Group D suffered symptoms all day. Physicians reported a significant number of barriers to implementing guidelines, eg, frequent lack of guideline updates, access to diagnostic procedures, and prescription-reimbursement issues. Conclusion: Our study confirms poor adherence to guidelines regarding treatment with an overuse of ICS and important barriers to implementation. A mismatch in classification occurs depending on the tool used, which can mislead clinicians in their choice of treatment.
AB - Purpose: GOLD guidelines classify COPD patients into A-D groups based on health status as assessed by COPD Assessment Test (CAT) or mMRC tools and exacerbations and recommend single or dual long-acting bronchodilators as maintenance therapy, with additional inhaled corticosteroids (ICS) if the disease remains uncontrolled. We aimed to classify primary care COPD patients into A-D groups, assess usual treatment and adherence to guidelines, potential mismatches between CATand mMRC-based classification and described symptoms within groups. Patients and methods: A total of 257 primary care COPD patients were enrolled between 2015 and 2016 in Greece. Physicians used structured interviews to collect cross-sectional data including demographics, symptoms, CAT, mMRC scores, and medications. Patients were classified into A-D groups based on CAT and mMRC, and prevalence of symptoms and medication was estimated within A-D groups. Interviews with physicians were also performed to explore additional issues about treatment and adherence to guidelines. Results: Mean (SD) age was 65 (12.3) years with 79% males. The majority of patients reported uncontrolled symptoms (91% and 61% with ≥10 CAT or ≥2 mMRC scores, respectively). Thirty-seven percentage had ≥2 exacerbations in the past year. Group B was the largest followed by Groups D, A, and C. Patients were classified as more severe by CAT than by mMRC. In all groups, the majority were treated with combined long-acting beta agonist/ICS (>50%). When patients were asked to report their main symptoms, dyspnea and cough were the most important symptoms mentioned, and there was a great variation between the A-D groups. However, Groups A-C reported mainly morning symptoms, whereas Group D suffered symptoms all day. Physicians reported a significant number of barriers to implementing guidelines, eg, frequent lack of guideline updates, access to diagnostic procedures, and prescription-reimbursement issues. Conclusion: Our study confirms poor adherence to guidelines regarding treatment with an overuse of ICS and important barriers to implementation. A mismatch in classification occurs depending on the tool used, which can mislead clinicians in their choice of treatment.
KW - Adherence
KW - CAT
KW - Classification
KW - COPD
KW - GOLD guidelines
KW - MMRC
KW - Symptoms
KW - Usual care
UR - https://www.scopus.com/pages/publications/85062985720
U2 - 10.2147/COPD.S185362
DO - 10.2147/COPD.S185362
M3 - Article
C2 - 30880944
AN - SCOPUS:85062985720
SN - 1176-9106
VL - 14
SP - 547
EP - 556
JO - International Journal of COPD
JF - International Journal of COPD
ER -